{
    "eid": "2-s2.0-85142302468",
    "title": "The clinical outcomes of high neutralizing antibodies titer convalescent plasma therapy in early developed severe COVID-19 patients; a case\u2013control study",
    "cover-date": "2022-12-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Microbiology (medical)",
            "@code": "2726",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Infectious Diseases",
            "@code": "2725",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [
        "Convalescent plasma",
        "COVID-19",
        "Mortality",
        "Severe COVID-19"
    ],
    "authors": [
        "Nuttakant Nontawong",
        "Taweegrit Siripongboonsitti",
        "Kriangkrai Tawinprai",
        "Mana Boonpratoom",
        "Nawin Krailassiri",
        "Chayaporn Boonkhum",
        "Kamonwan Soonklang",
        "Yong Poovorawan",
        "Nithi Mahanonda"
    ],
    "citedby-count": 1,
    "ref-count": 33,
    "ref-list": [
        "COVID-19 Coronavirus Pandemic",
        "Convalescent plasma antibody levels and the risk of death from Covid-19",
        "Hark back: passive immunotherapy for influenza and other serious infections",
        "Serum therapy revisited: animal models of infection and development of passive antibody therapy",
        "Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment?",
        "Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection",
        "Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial",
        "Treatment of coronavirus disease 2019 (COVID-19) patients with convalescent plasma",
        "Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial",
        "Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial)",
        "A randomized trial of convalescent plasma in Covid-19 severe pneumonia",
        "Safety update: COVID-19 convalescent plasma in 20,000 hospitalized patients",
        "Early safety indicators of COVID-19 convalescent plasma in 5000 patients",
        "Deployment of convalescent plasma for the prevention and treatment of COVID-19",
        "Return to the past: the case for antibody-based therapies in infectious diseases",
        "Evidence favouring the efficacy of convalescent plasma for COVID-19 therapy",
        "The convalescent sera option for containing COVID-19",
        "Infectious diseases society of america guidelines on the treatment and management of patients with COVID-19",
        "Effect of convalescent plasma on mortality among hospitalized patients with COVID-19: initial three-month experience",
        "A randomized double-blind controlled trial of convalescent plasma in adults with severe COVID-19",
        "Effect of convalescent plasma on organ support-free days in critically Ill patients with COVID-19: a randomized clinical trial",
        "Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial",
        "A multicenter randomized open-label clinical trial for convalescent plasma in patients hospitalized with COVID-19 pneumonia",
        "Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection",
        "The therapeutic effectiveness of Convalescent plasma therapy on treating COVID-19 patients residing in respiratory care units in hospitals in Baghdad, Iraq",
        "Use of convalescent plasma therapy in SARS patients in Hong Kong",
        "Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial",
        "Convalescent plasma treatment of severe COVID-19: a propensity score\u2013matched control study",
        "Initial experience in Mexico with convalescent plasma in COVID-19 patients with severe respiratory failure, a retrospective case series",
        "Early outpatient treatment for Covid-19 with convalescent plasma",
        "Early high-titer plasma therapy to prevent severe Covid-19 in older adults"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "@id": "60022464",
            "affilname": "Chulabhorn Royal Academy",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60022464",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60002620",
            "affilname": "Faculty of Medicine, Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002620",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Pathum Thani",
            "@id": "128867790",
            "affilname": "Naungsau Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/128867790",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Pathum Thani",
            "@id": "128867456",
            "affilname": "Prachathiput Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/128867456",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": [
        "National Blood Center",
        "Chulabhorn Royal Academy",
        "Chulalongkorn University"
    ]
}